Differential propensity for major hemorrhagic events in patients with different types of arterial disease

被引:10
作者
Achterberg, S. [1 ]
Visseren, F. L. J. [2 ]
Kappelle, L. J. [1 ]
Pruissen, D. M. O. [1 ]
Van der Graaf, Y. [3 ]
Algra, A. [1 ,3 ]
机构
[1] Univ Med Ctr Utrecht, Dept Neurol, Utrecht Stroke Ctr, Rudolf Magnus Inst Neurosci, NL-3508 GA Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands
关键词
cerebrovascular disorders; coronary disease; follow-up; genetics; hemorrhage; peripheral vascular disease; CEREBRAL-ISCHEMIA; VASCULAR EVENTS; ASSOCIATION; ASPIRIN; THERAPY; RISK;
D O I
10.1111/j.1538-7836.2011.04437.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Atherosclerosis is the most frequent cause of coronary artery disease (CAD), cerebrovascular disease (CVD), and peripheral arterial obstructive disease (PAD). We previously found that patients with CVD or PAD had a two-fold higher risk of major hemorrhagic complications than patients with CAD. We investigated whether this difference was attributable to baseline risk factors or genetic variants involved in hemostasis. Methods and results: We included 2622 consecutive patients from a single university hospital who presented with non-disabling CAD, CVD, or PAD. All patients were followed for the occurrence of major hemorrhagic complications for a mean of 6.6 years. Major hemorrhagic events included intracranial hemorrhagic events, fatal hemorrhagic events, and any hemorrhagic complications requiring hospitalization, irrespective of interventions. Major hemorrhagic complications occurred in 122 patients (annual event rate of 0.77%). Patients with CVD or PAD had more hemorrhagic complications than patients with CAD(hazard ratio [HR] 2.05, 95% confidence interval [CI] 1.39-3.01). Hypertension, diabetes, renal failure and use of oral anticoagulants or antiplatelet therapy did not explain the difference (HR adjusted for all characteristics 1.74; 95% CI 1.14-2.61). Additional adjustment for genetic variants did not further change the HR. Conclusion: Patients with CVD or PAD are at higher risk for major hemorrhagic events than patients with CAD. This difference could not be explained by known risk factors, use of antithrombotic agents, or genetic variants involved in hemostasis. Further research to find the reason for this difference and possible differences in pathogenesis is warranted.
引用
收藏
页码:1724 / 1729
页数:6
相关论文
共 16 条
  • [1] Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study
    Achterberg, Sefanja
    Cramer, Maarten J. M.
    Kappelle, L. Jaap
    de Borst, Gert Jan
    Visseren, Frank L. J.
    van der Graaf, Yolanda
    Algra, Ale
    [J]. EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 (04): : 424 - 430
  • [2] Amarenco P, 2006, NEW ENGL J MED, V355, P549
  • [3] ACC/AHA 2007 guide lines for the management of patients with unstable Angina/Non-ST-Elevation myocardial infraction - Executive summary
    Anderson, Jeffrey L.
    Adams, Cynthia D.
    Antman, Elliott M.
    Bridges, Charles R.
    Califf, Robert M.
    Casey, Donald E., Jr.
    Chavey, William E., II
    Fesmire, Francis M.
    Hochman, Judith S.
    Levin, Thomas N.
    Lincoff, A. Michael
    Peterson, Eric D.
    Theroux, Pierre
    Wenger, Nanette Kass
    Wright, R. Scott
    Smith, Sidney C., Jr.
    Jacobs, Alice K.
    Adams, Cynthia D.
    Riegel, Barbara
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) : 652 - 726
  • [4] Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
  • [5] Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care
    Cohen, Marc
    [J]. MAYO CLINIC PROCEEDINGS, 2009, 84 (02) : 149 - 160
  • [6] Coronary atherosclerosis and cardiovascular mortality in hemophilia
    Foley, C. J.
    Nichols, L.
    Jeong, K.
    Moore, C. G.
    Ragni, M. V.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (01) : 208 - 211
  • [7] Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial
    Halkes, P. H. A.
    van Gijn, J.
    Kappelle, L. J.
    Koudstaal, P. J.
    Algra, A.
    [J]. LANCET NEUROLOGY, 2007, 6 (02) : 115 - 124
  • [8] Hirsch AT, 2006, CIRCULATION, V113, pE463, DOI 10.1161/CIRCULATIONAHA.106.174526
  • [9] Polymorphisms of platelet adhesive receptors:: Do they play a role in primary intracerebral hemorrhage?
    Iniesta, JA
    Corral, J
    González-Conejero, R
    Piqueras, C
    Vicente, V
    [J]. CEREBROVASCULAR DISEASES, 2003, 15 (1-2) : 51 - 55
  • [10] Bleeding with anticoagulation therapy - Who is at risk, and how best to identify such patients
    Palareti, Gualtiero
    Cosmi, Benilde
    [J]. THROMBOSIS AND HAEMOSTASIS, 2009, 102 (02) : 268 - 278